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ABSTRACT  
Background/Aims: A new prognostic staging system, the SLiDe (S, stage; Li, liver 
damage; De, des-gamma-carboxy prothrombin) score was recently proposed.  We 
examined 207 HCC patients following hepatic resection to determine the usefulness of 
this staging system for HCC patients after surgery,. 
Methodology: Disease-free and overall survival rates were calculated according to the 
Kaplan-Meier method, and differences between groups were tested for significance 
using the log-rank test.  
Results: Regarding disease-free survival, there were no significant differences in 
survival between SLiDe score 0 vs 1, between score 2 vs 3, and between score 4 vs 5.  
There were significant differences between 0-1 vs 2-3 (p<0.01) and between 2-3 vs 4-5 
(p<0.01).  Regarding overall survival, there were no significant differences in survival 
between score 0 vs 1, between score 2 vs 3, and between score 4 vs 5.  There were 
significant differences between 0-1 vs 2-3 (p<0.05) and between 2-3 vs 4-5 (p<0.01).  
Conclusions: The SLiDe score, a staging system that combines tumor factors, a tumor 
marker and hepatic function, might be a better predictor of prognosis in HCC patients 
who have undergone hepatic resection. 
KEY WORDS: Hepatocellular carcinoma; SLiDe score; Hepatectomy 
ABBREVIATIONS: S, stage; Li, liver damage; De, des-gamma-carboxy prothrombin 
(SLiDe) score, Japan Integrated Staging System (JIS) 
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INTRODUCTION 
The establishment of new staging systems for hepatocellular carcinoma (HCC) has 
been recently reported worldwide, with discussions on the strengths of each system 
(1-6).  In addition to tumor staging, the degree of hepatic function is also necessary to 
determine the prognosis of HCC patients (1, 3, 4).  The effectiveness of combined 
staging systems has already been confirmed such as the Italian Cancer of the Liver 
Program (CLIP) (1), Barcelona Clinic Liver Cancer (BCLC) staging (2), the Japan 
Integrated Staging (JIS) score (3), the Construction of the Chinese University 
Prognostic Index (CUPI) score (4), the Groupe d'Etude et de Traitement du Carcinome 
Hepatocellulaire (GETCH) score (5), and the Tokyo score (6).  In patients who 
underwent surgical resection, the appropriate staging of hepatic function instead of the 
Child-Pugh classification is expected because the majority of patients show good 
hepatic function.  Sensitive tumor markers for HCC have been established.  As the 
alpha fetoprotein (AFP) level does not always reflect malignancy, des-gamma-carboxy 
prothrombin (protein induced by vitamin K absence or the antagonist II;PIVKA-II) has 
been widely used to diagnose HCC in the last decade (7).  Our group has proposed the 
effectiveness of the modified CLIP score using protein induced by vitamin K absence or 
antagonist II (PIVKA-II), instead of AFP concentration used in the original CLIP (8, 9).  
Omagari et al. recently proposed a new staging system called the SLiDe score, 
consisting of the Japanese TNM stage, Liver Damage grade and the serum level of 
des-gamma-carboxy prothrombin (DCP) based on a reasonable examination in HCC 
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patients using multivariate analysis (10).  This staging system might well match the 
current status for evaluating HCC patients after hepatectomy. 
 It is difficult to simultaneously evaluate HCC patients who have undergone 
various modalities such as hepatectomy, local ablation therapy or chemoembolization.  
Therefore, in this study, we applied the SLiDe score to evaluate patient survival in 207 
HCC patients who underwent hepatic resection at several cancer institutions in 




Data from 207 HCC patients (175 males, 32 females) who underwent surgery at the 
Division of Surgical Oncology, Department of Translational Medical Sciences, 
Nagasaki University Graduate School of Biomedical Sciences (NUGSBS) and its 
associated hospitals between January 1994 and December 2004 were retrospectively 
collected.  Patients with tumor residues after hepatectomy were excluded from this 
study.  Prior to surgery for HCC, 72 patients were treated with either 
chemoembolization (n=65), alcohol injection (n=3) or a combination of these two 
modalities (n=4); however, tumors were not completely controlled in these patients.  
After surgery, 4 patients received adjuvant 5-fluorouracil chemotherapy by intra-arterial 
injection through a subcutaneously implanted reservoir to prevent tumor recurrence; 
however, there were no definite indications of adjuvant treatments before and after 
hepatectomy in our patients at this stage.  Of 132 patients (64%) with tumor recurrence 
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after hepatectomy (liver [n=124], bone [n=4], lung [n=2] and lymph node [n=2]), 68 
patients received chemoembolization, 29 alcohol injection, 5 re-resection, 7 ablation 
therapy, 5 received intravenous chemotherapy as the second line treatment and 18 
patients received no adjuvant therapies.  
The indication of operation was limited to Child A patients and some Child B 
patients (11).  The volume of liver to be resected was estimated according to the results 
of the indocyanine green retention rate at 15 min (ICG R15) using Takasaki’s formula 
(12).  The expected liver volume for resection, excluding the tumor (cm3) was 
measured by computed tomography (CT) volumetry (13).  Operative procedures 
included lobectomy or extended lobectomy (n=57), segmentectomy or 
subsegmentectomy (n=65), and partial resection (n=85).  Radical hepatectomy was 
performed to remove the hepatic tumor without leaving any residual tumor.  
The study was approved by the Ethics Review Board of our department at the 
NUGSBS.  Mortality and morbidity data were collected from the NUGSBS database, 
and provided through collaborating with associated hospitals. 
 
Measurement of tumor marker 
A peripheral blood sample (4 mL) for tumor marker measurement was collected from 
each patient and centrifuged at 3,000 rpm (1,000  g) for 10 minutes.  DCP was 
assayed by an enzyme-linked immunoassay using Eitest ® PIVKA-II (Sanko Junyaku 
Co., Tokyo, Japan).  Up to 1996, the minimum measured value of DCP was 100 
mAU/mL. After 1997, the normal value was determined as <40 mAU/mL.  
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Staging criteria  
We used the pathological tumor-node-metastasis (pTNM) classification system of the 
Liver Cancer Study Group of Japan in 2000 (Table 1) (14).  The Liver Damage Grade 
by the Liver Cancer Study Group of Japan was used for hepatic function staging (Table 
2) (14).  The sum of the score in each parameter (TNM stage, Liver damage grade and 
DCP) was counted in the SLiDe scoring system (Table 3) (15). 
 
Statistical analysis 
Disease-free and overall survival rates were calculated according to the Kaplan-Meier 
method, and differences between groups were tested for significance using the log-rank 
test.  A two-tailed P value of < 0.05 was considered significant in this study.  
Statistical analyses were performed using SAS software (Statistical Analysis System 




The mean age of the patients at the time of surgery was 63 ± 9 years (range, 28-81 
years).  Background liver abnormalities included chronic viral hepatitis in 113 patients 
(55%), cirrhosis in 85 (41%), hepatic fibrosis in 4 (2%) and normal liver in 5 (2%), 
associated with hepatitis virus B (n=68), hepatitis virus C (n=116), both hepatitis B and 
C (n=5), or non-B non-C hepatitis (n=18).  Concerning the PIVKA-II level, 85 patients 
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showed a value ≥400mAU/ml (41%).  According to the Liver Damage grade, 159 
patients were classified as A (77%) and 48 (23%) as B. 
 
Patient survival 
Figure 1 shows the disease-free and overall survival associated with the SLiDe score.  
With respect to disease-free survival, there were no significant differences in survival, 
between score 0 vs 1, between score 2 vs 3, and between score 4 vs 5.  There were 
significant differences between 0, 1 vs 2, 3 (p<0.01) and between 2, 3 vs 4, 5 (p<0.01).  
With respect to overall survival, there were no significant differences in survival, 
between score 0 vs 1, between score 2 vs 3, and between score 4 vs 5.  There were 
significant differences between 0, 1 vs 2, 3 (p<0.05) and between 2, 3 vs 4, 5 (p<0.01). 
 
DISCUSSION 
European and Asian institutes have recently proposed new staging systems with 
potentially superior capability for predicting survival in HCC patients compared to the 
TNM system (1-7, 15, 16); however, the superiority of these staging systems has not 
been fully demonstrated with reliable statistical analysis as evidence of their 
applicability.  
Kudo et al. have reported the usefulness of JIS staging, which has superior 
prognostic capabilities for the survival of HCC patients when compared to the CLIP 
score (3, 17).  The JIS score consists of the Japanese TNM stage and Child-Pugh 
classification although the majority of patients had Child-Pugh A disease and even 
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patients with Child-Pugh B had no encephalopathy, ascites or significant 
hyperbilirubinemia in HCC patients undergoing surgical resection in this series.  
Therefore, HCC patients who underwent surgery might be classified using other 
classifications of hepatic function.  The liver damage grade based on the value of the 
indocyanine green retention rate at 15 minutes (ICG R15) was appropriate to 
individualize the population of HCC patients compared to using the Child-Pugh 
classification.  ICGR15 is an estimation of indocyanine green clearance; this parameter 
has been widely used in the field of surgery in Japan as a useful marker of hepatic 
function (12, 13).  ICGR15 is a significant prognostic factor in HCC patients with or 
without cirrhosis (18).  In the SLiDe score (10), the TNM stage and liver damage 
grade were included.  Furthermore, the DCP level was also applied in this staging 
system.  This parameter was thought to be useful for predicting poor patient survival.  
In our preliminary study, a higher PIVKA-II level after treatment might also reflect poor 
survival compared to the AFP level in HCC patients undergoing hepatectomy (in-press, 
HBP).  The SLiDe score consisting of these 3 powerful parameters was thought to be 
more reliable compared to other combined staging systems.  Omagari et al. reported 
that the SliDe classification showed a lower AIC score compared with the JIS and CLIP 
score in HCC patients treated with other modalities, indicating that it was the most 
appropriate system (10).  
This study revealed that the discrimination of disease-free and overall survival 
between scores is good; however, discrimination between 0 vs 1, 2 vs 3, and 4 vs 5 was 
not significant, respectively.  Therefore, these populations could be divided into 3 
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subgroups (score 0-1, 2-3, and 4-5).  Omagari et al. also reported in their original 
manuscript that SLiDe 0 and 1, or SLiDe 4, 5 and 6 needed to be joined, respectively.  
Our future goal is to clarify the superiority of this staging system by comparing with 
other reliable staging systems in a larger number of HCC patients using multivariate 
analysis for patient survival (10). 
 In conclusion, we conducted a retrospective analysis of prognosis using a new 
staging system called the SLiDe score in 207 Japanese HCC patients who underwent 
hepatic resection.  The discrimination ability of disease-free and overall survival 
between SLiDe 0-1 and 2-3 and 4-5 was statistically significant, respectively.  The 
staging systems, combined with tumor-related factors, sensitive tumor markers and 
hepatic function are useful predictors of HCC prognosis. 
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TABLE 1 Definition of Tumor Node Metastasis Classification  





Agree with all 3 criteria 
Agree with 2 of 3 criteria 
Agree with 1 of 3 criteria 
Agree with no criteria 
N0 
N1 
No metastasis to lymph nodes 
Metastasis to lymph nodes 
M0 
M1 










T4N0M0 or any T N1M0 
Any T N0-1 M1 
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TABLE 2 Definition of Liver Damage Grade  
 A B C 
Ascites 
Serum bilirubin (mg/dL) 
Serum albumin (g/dL) 
ICG R15 (%) 
















ICG R15; Indocyanine green retention rate at 15 minutes 
TABLE 3 Classification of SLiDe Score 














DCP, des-γ-carboxy prothrombin 
















FIGURE 1 Kaplan-Meier disease-free (A) and overall survival (B) curves in patients 
who underwent hepatectomy for HCC by SLiDe score. 
